By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Ascendis Pharma A/S 

Tuborg Boulevard 12

Hellerup    DK-2900  Denmark
Phone: 45-36-94-44-86 Fax: 45-36-94-40-10


SEARCH JOBS



Segment
Start Up





Company News
Growth Hormone Biotech Ascendis Pharma A/S Files For A $86 Million IPO 12/19/2014 6:57:41 AM
Ascendis Pharma A/S Announces Positive Six-Month Interim Results From A Phase 2 Pediatric Study Of Once-Weekly Transcon Growth Hormone For The Treatment Of Growth Hormone Deficiency 12/15/2014 7:37:13 AM
Ascendis Pharma A/S Completes $60 Million Oversubscribed Series D Financing 12/1/2014 9:13:01 AM
Ascendis Pharma A/S Announces Positive Interim Results From A Phase 2 Pediatric Study Of Once-Weekly Transcon Growth Hormone For The Treatment Of Growth Hormone Deficiency 9/16/2014 9:47:34 AM
Ascendis Pharma A/S Eyes Second Medical Device Sector Deal 6/13/2014 7:01:16 AM
Ascendis Pharma A/S Appoints Martin Auster, M.D., As Chief Business Officer 6/2/2014 7:17:27 AM
Ascendis Pharma A/S Announces The Appointment Of Thomas P. Soloway As Chief Financial Officer 1/10/2014 6:28:53 AM
United Therapeutics Corporation (UTHR) Announces Collaboration With Ascendis Pharma A/S to Develop Self-Injectable Treprostinil for Pulmonary Arterial Hypertension 9/20/2012 10:58:33 AM
Novo Nordisk A/S (NVO), Eli Lilly and Company (LLY), And Novartis AG Said to Bid for Ascendis Pharma A/S; Offer is Rumored to be About $400 Million 8/2/2010 8:28:14 AM
Ascendis Pharma A/S Initiates Phase I Clinical Study Of ACP-001, A Once-Weekly Human Growth Hormone Product 11/10/2009 1:59:47 PM
12
//-->